Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Cash Ratio is 9.99 as of Mar. 2026, which is 8% below its 10-year median of 10.90. The stock has 1 warning sign investors should review. Among 208 Medical Diagnostics & Research companies, Invitro International ranks better than 95.67% on this metric.
Invitro International has a Cash Ratio of 9.99. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Invitro International's Cash Ratio or its related term are showing as below:
IVRO'
s Cash Ratio Range Over the Past 10 Years
Min: 9.86 Med: 10.9 Max: 13.52
Current: 9.99
During the past 9 years, Invitro International's highest Cash Ratio was 13.52. The lowest was 9.86. And the median was 10.90.
IVRO's Cash Ratio is ranked better than 95.67% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.945
vs IVRO: 9.99
Invitro International (OTCPK:IVRO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Invitro International's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Cash Ratio of 9.99 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Invitro International and its competitors. This is near median its historical median of 10.90. Over the past decade, Invitro International's Cash Ratio has ranged from 9.86 to 13.52. According to the industry distribution chart, Invitro International ranks #9 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 4.3%.
Is Invitro International's Cash Ratio too high?
Invitro International's current Cash Ratio of 9.99 is near median its 10-year median of 10.90. Over the past 10 years, this metric has ranged from a low of 9.86 to a high of 13.52. The Medical Diagnostics & Research industry median Cash Ratio is 0.95. Invitro International's value of 9.99 is 957.1% above this industry median. Based on the distribution chart, Invitro International ranks #9 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's Cash Ratio compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #9 out of 208 companies for Cash Ratio. This places Invitro International in the top 4% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.95. Invitro International's value of 9.99 is 957.1% above this benchmark. Historically, Invitro International's own Cash Ratio has ranged from 9.86 to 13.52 over the past decade. While the company's 10-year median is 10.90 vs. the industry median of 0.95, Invitro International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.95, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Cash Ratio of 9.99 is 957.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Cash Ratio is 9.99, which is near median its own 10-year median of 10.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Cash Ratio is 9.99, which is near median its 10-year median of 10.90 and 957.1% above the Medical Diagnostics & Research industry median of 0.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Invitro International (IVRO), the current Cash Ratio is 9.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
